234 related articles for article (PubMed ID: 31840521)
21. (99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.
García MF; Zhang X; Shah M; Newton-Northup J; Cabral P; Cerecetto H; Quinn T
Bioorg Med Chem; 2016 Mar; 24(6):1209-15. PubMed ID: 26875936
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
[No Abstract] [Full Text] [Related]
23. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
24. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
25. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
27. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
28. Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue.
Goos JACM; Davydova M; Dilling TR; Cho A; Cornejo MA; Gupta A; Price WS; Puttick S; Whittaker MR; Quinn JF; Davis TP; Lewis JS
Nucl Med Biol; 2020; 84-85():63-72. PubMed ID: 32135473
[TBL] [Abstract][Full Text] [Related]
29. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
30. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
31. Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody.
Rossin R; Läppchen T; van den Bosch SM; Laforest R; Robillard MS
J Nucl Med; 2013 Nov; 54(11):1989-95. PubMed ID: 24092936
[TBL] [Abstract][Full Text] [Related]
32. Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models.
Rondon A; Ty N; Bequignat JB; Quintana M; Briat A; Witkowski T; Bouchon B; Boucheix C; Miot-Noirault E; Pouget JP; Chezal JM; Navarro-Teulon I; Moreau E; Degoul F
Sci Rep; 2017 Nov; 7(1):14918. PubMed ID: 29097747
[TBL] [Abstract][Full Text] [Related]
33. PSMA-targeted bispecific Fab conjugates that engage T cells.
Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
[TBL] [Abstract][Full Text] [Related]
34. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
35. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
36. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
37. Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.
Moffett S; Mélançon D; DeCrescenzo G; St-Pierre C; Deschénes F; Saragovi HU; Gold P; Cuello AC
Hybridoma (Larchmt); 2007 Dec; 26(6):363-72. PubMed ID: 18158780
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Taylor RM; Sillerud LO
Int J Nanomedicine; 2012; 7():4341-52. PubMed ID: 22915856
[TBL] [Abstract][Full Text] [Related]
39. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
Alt K; Wiehr S; Ehrlichmann W; Reischl G; Wolf P; Pichler BJ; Elsässer-Beile U; Bühler P
Prostate; 2010 Sep; 70(13):1413-21. PubMed ID: 20687214
[TBL] [Abstract][Full Text] [Related]
40. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]